Business
Senti Biosciences spins out gene-circuit pipeline into NewCo to focus on Regulator Dial platform
South San Francisco-based Senti Biosciences Holdings (Nasdaq: SNTI) is divesting its gene-circuit-enabled pipeline — including its most advanced clinical...
Septa acquires CeeNU from BMS to end Canada's critical chemotherapy shortage
Mississauga, Ontario-based Septa Pharmaceuticals has acquired CeeNU (lomustine) from Bristol Myers Squibb (NYSE: BMY) Canada, effective June 29, 2026,...
Crescent Bio to raise USD 125m to provide oncology pipeline runway into 2028
Waltham, Massachusetts-based Crescent Biopharma, Inc. (Nasdaq: CBIO) announced the pricing of an underwritten public offering of ordinary shares and...
Q32 Bio raises USD 200m on heels of Phase II win for alopecia areata therapy
Waltham, Massachusetts-based Q32 Bio Inc. (Nasdaq: QTTB) announced a proposed underwritten public offering of common stock and pre-funded warrants targeting...
Adneuris launches with US NDA plans for cebranopadol, signs first China licensing deal with Conba
Monmouth Junction, New Jersey-based Adneuris Therapeutics launched July 9 as a wholly-owned subsidiary of Tris Pharma, established to advance cebranopadol,...
Agenus raises up to USD 340 million as it shifts BOT+BAL focus to neoadjuvant colon cancer
Lexington, Massachusetts-based Agenus Inc. (Nasdaq: AGEN) announced an oversubscribed private placement of up to USD 340 million to fund the ROBBIN Phase...
Erasca raises USD 550m on strong demand for RAS-targeting precision oncology pipeline
San Diego-based Erasca, Inc. (Nasdaq: ERAS) announced the pricing of an upsized underwritten public offering of common stock, raising approximately USD 550...
Draig Therapeutics secures USD 65m Series B to advance neuropsychiatric receptor modulators
UK-based Draig Therapeutics has closed an oversubscribed USD 65 million Series B financing round to accelerate clinical development of its pipeline of AMPA...
AI drug designer Chai Discovery triples valuation to USD 3.8b after USD 400m Series C
San Francisco-based Chai Discovery has closed a USD 400 million Series C financing round at a USD 3.8 billion valuation, reflecting a near-tripling of its...
Lyora Therapeutics launches with USD 2.5m seed funding for inherited retinal disease genetic medicines
Providence, Rhode Island-based Lyora Therapeutics has emerged from stealth with USD 2.5 million in pre-seed financing and a two-program pipeline of genetic...
Spero secures USD 105m non-dilutive financing backed by Utebzi royalties
Cambridge, Massachusetts-based Spero Therapeutics (Nasdaq: SPRO) announced a USD 105 million non-recourse, non-dilutive royalty financing with affiliates of...
Spero expands into autoimmune disease via USD 1.1b Innovent anti-CD40L deal
Spero Therapeutics in-licenses Innovent's Fc-silent anti-CD40L antibody in up to USD 1.1 billion deal, marking a full pivot from antibiotics to autoimmune
AstraZeneca pays USD 600m upfront to reacquire worldwide rights to former China R&D asset from Dizal
AstraZeneca has entered a global exclusive license agreement with China-based Dizal Pharmaceutical (SSE: 688192) for Zegfrovy (sunvozertinib), an oral...
Hansoh extends cross-border licensing strategy with Avere Nasdaq deal, highlighting evolution of biotech “NewCo” model
Private US-based Avere Therapeutics, Inc. has entered into a definitive all-stock merger agreement with NextCure, Inc. (Nasdaq: NXTC), a US-based...
Alto Neuroscience raises USD 100m through stock offering as depression candidate enters Phase III
Mountain View, California-based Alto Neuroscience, Inc. (NYSE: ANRO) announced the pricing of an underwritten registered direct offering of common stock,...
The AllSci Brief
Systematic R&D and deal news. Daily.